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Abstract
Background: Blood transfusion is associated with acute kidney injury (AKI) after
transcatheter aortic valve implantation (TAVI). We sought to elucidate in more
detail the relation between blood transfusion and AKI and its effects on short- and
long-term mortality. Methods and Results: Nine hundred ninety-five patients with
aortic stenosis underwent TAVI with the Medtronic CoreValve or the Edwards
Valve in 7 centers. AKI was defined by the Valve Academic Research Consortium
(absolute increase in serum creatinine ≥0.3 mg/dL [≥26.4 μmol/L] or ≥50%
increase <72 hours). Logistic and Cox regression was used for predictor and
survival analysis. AKI occurred in 20.7% (n=206). The number of units of blood
transfusion <24 hours was the strongest predictor of AKI (≥5 units, OR, 4.81
[1.45-15.95], 3-4 units, OR, 3.05 [1.24-7.53], 1-2 units, OR, 1.47 [0.98-2.22])
followed by peripheral vascular disease (OR, 1.48 [1.05-2.10]), history of heart
failure (OR, 1.43 [1.01-2.03]), leucocyte cou...
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Transcatheter aortic valve implantation (TAVI) is increasingly used to treat patients with aortic stenosis, 
who are considered at high risk for surgical aortic valve 
replacement.1 Despite its minimally invasive nature, TAVI 
is invariably associated with a number of complications 
that may affect outcome. Some of these complications are 
clinically manifest during the procedure for which imme-
diate actions are taken, whereas others such as acute kid-
ney injury (AKI) are detected later and may have silent, but 
harmful, prognostic effects. AKI is reported in 12% to 57% 
of the patients who undergo TAVI and is associated with a 
2- to 6-fold increased risk of death during short- and long-
term follow-up.2–10
At present, the pathophysiologic mechanisms of AKI after 
TAVI are unclear. Some studies suggest a direct relation 
between perioperative blood transfusion and AKI.5,6,10 This 
may be explained by the fact that in association with the 
transfusion of red blood cells (RBC) a number of other cellular 
and molecular substances are administrated that either directly 
or indirectly (eg, inflammation) induce kidney damage,11 yet 
one may question whether the triggers for blood transfusion, 
such as perioperative blood loss because of bleeding-vascular 
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complications may also play a role. This also holds for the 
presence of baseline anemia, impaired kidney function, and 
other procedural factors such as changes in cardiovascular 
hemodynamics during TAVI.7,12 We, therefore, sought to 
explore in more detail the relation between blood transfusion 
and AKI after TAVI relative to a number of baseline and 
procedural variables in a series of 995 patients in addition to 
the effects of blood transfusion and AKI on mortality.
Methods
Patients
Between November 2005 and January 2012, 1050 patients with aor-
tic stenosis underwent TAVI with the Medtronic CoreValve System 
(Medtronic Inc) or the Edwards SAPIEN Valve (Edwards Life 
 Sciences) in the Erasmus Thoraxcenter, Rotterdam, The Netherlands 
(n=220); Quebec Heart and Lung Institute, Quebec City, Quebec, 
Canada (n=216); University Hospital Bonn, Bonn, Germany (n=182); 
University Hospital Maastricht, Maastricht, The Netherlands (n=145); 
University Hospital Saint-Luc, Brussels, Belgium (n=122); University 
Hospital Antwerp, Antwerp, Belgium (n=97); and Angiografia 
de Occidente, Cali, Colombia (n=68). Patients on chronic hemo-
dialysis (n=35) and those who died within 72 hours precluding 
creatinine measurements during the first 3 days after TAVI (n=23— 
including 3 patients on chronic hemodialysis [causes of death are 
listed in online-only Data Supplement]) were excluded from the 
study. The final study population consisted, therefore, of 995 patients.
In each institution, patients with symptomatic aortic stenosis were 
screened at the outpatient clinic during which a structured interview, 
physical examination, ECG, and blood sampling were performed. 
Invasive diagnostic workup included a left heart catheterization 
(performed by the referring institution in most patients) to determine 
the coronary anatomy and hemodynamic status; echo-(Doppler) car-
diography (transthoracic or transesophageal), contrast angiography, 
or contrast enhanced multisliced CT were performed >2 weeks before 
TAVI to assess the valvular and vascular anatomy and to define the 
vascular access strategy (transfemoral, transapical, transsubclavian, 
transaortic). Treatment eligibility was based on previously described 
patient-selection criteria, and final acceptance for TAVI was estab-
lished by Heart Team consensus.13
In accordance with the institutions policies, every patient gave 
written informed consent for TAVI and the use of anonymous 
clinical, procedural and follow-up data for research in accordance 
with Institutional Review Board approval. This study complies with 
the Declaration of Helsinki.
Procedure
TAVI was performed under general or local anesthesia using the 
Medtronic CoreValve System (26, 29, or 31 mm) or Edwards 
SAPIEN Valve (20, 23, or 26 mm) via a transfemoral, transapical, 
transsubclavian, or transaortic approach of which details have been 
described previously.14–18 Details of the prehydration protocol for the 
various institutions are summarized in online-only Data Supplement.
The amount of contrast and the occurrence of life-threatening ar-
rhythmias (any episode of ventricular tachycardia, ventricular fibril-
lation, asystole requiring vasopressive drugs, electric defibrillation, or 
cardiopulmonary resuscitation), any complication leading to severe 
sustained hypotension, postimplantation balloon dilation, and (Valve 
Academic Research Consortium-defined) bleeding and vascular com-
plications were recorded during or immediately after TAVI.19
After the procedure, patients were extubated in the catheteriza-
tion room or after transfer in the cardiac care unit shortly after the 
procedure or later if clinically indicated. Antiplatelet therapy after 
Medtronic CoreValve System and Edwards SAPIEN Valve im-
plantation consisted of clopidogrel 75 mg for 6 months and aspirin 
80 to 100 mg indefinitely. Patients on oral anticoagulant therapy 
 before TAVI received periprocedural therapeutic anticoagulation 
with unfractionated heparin or low-molecular-weight heparin in 
combination with either clopidogrel or aspirin to cover the time 
with subtherapeutic INR levels. Oral anticoagulation was resumed 
shortly after TAVI.
Laboratory Measurements and AKI Definition
Preoperative serum creatinine (SCr) values were used to calculate the 
baseline SCr clearance using the Cockcroft and Gault equation: SCr 
clearance (mL/min)=(140−age)×weight (kg)÷72×SCr (mg/dL) (×0.85 
for women).20 Chronic kidney disease (CKD) was defined as a calcu-
lated SCr clearance <60 mL/min.21,22 Patients with CKD were further 
classified in tertiles to examine the effect of mild (45.0–60.0 mL/min), 
moderate (35.0–44.9 mL/min), and severe CKD (<35 mL/min).
AKI was defined according to the Valve Academic Research 
Consortium recommendations as an absolute (≤72 hours) reduction in 
kidney function and defined as: (1) an absolute increase in the highest 
value of SCr ≥0.3 mg/dL (≥26.4 μmol/L) or (2) a percentage increase 
in the highest value of SCr ≥50% (1.5-fold from baseline). AKI sever-
ity was further classified as stage I (increase in SCr of 150%–200% 
or increase of ≥0.3 mg/dL ≥26.4 μmol/L]), stage II (increase in SCr 
of 200%–300%), or stage III (increase in SCr of ≥300% or increase 
of ≥4.0 mg/dL [≥354 μmol/L]) with an acute increase of ≥0.5 mg/dL 
(44 μmol/L). Patients receiving renal replacement therapy (hemody-
alysis, peritoneal dialysis, or hemofiltration) during hospitalization or 
within 30 days after the procedure were considered to be classified 
as stage III.19
Preoperative hemoglobin (Hb) values were used to define baseline 
anemia according to the American College of Physicians and WHO 
criteria as a Hb level <13 g/dL in men and <12 g/dL in women.23 
Patients with anemia were classified in tertiles to assess the effects of 
mild (12.0–12.99 g/dL in men; 11.30–11.99 g/dL in women), mod-
erate (10.80–11.99 g/dL in men; 10.23–11.29 g/dL in women), and 
severe anemia (<10.80 g/dL in men, <10.23 g/dL in women).
Data on RBC transfusions were recorded by the institution’s blood 
bank laboratory and used to determine the corrected Hb drop ≤24 
hours after TAVI according to the modified Landefeld equation.24,25 
In this equation 1 unit of packed RBCs is considered to represent 
1 g/dL of Hb and, therefore, the net Hb drop corresponds to the ad-
dition of the number of packed RBC to the baseline-minus-measured 
nadir Hb.12
Follow-Up
After hospital discharge, mortality data were collected by contacting 
the civil registries or the referring physician or general practitioner 
WHAT IS KNOWN
•	Perioperative blood transfusion has been associated 
with acute kidney injury after transcatheter aortic 
valve implantation.
WHAT THE STUDY ADDS
•	Blood transfusion was the most important factor as-
sociated with acute kidney injury whereas potential 
triggers of transfusion, such as baseline anemia,  
vascular-bleeding complications, blood loss, or se-
vere hypotension, were not.
•	Patients	with	anemia	had	less	decline	in	hemoglobin		
after	 transcatheter	 aortic	 valve	 implantation	but	 re-
ceived	more	transfusions	as	compared	with	patients	
without	anemia.
•	Acute kidney injury was a predictor of both short- 
and long-term mortality whereas blood transfusion 
predicted long-term mortality.
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and was complete in 98.4% of the 937 patients who survived the 
first 30 days (median [interquartile range] follow-up time; 12 [4–23] 
months). Death at any time during the follow-up period was classified 
as cardiac or noncardiac according to the Valve Academic Research 
Consortium criteria.19
Statistical Analysis
Details of data completeness and management are summarized in 
online-only Data Supplement. Categorical variables are presented as 
frequencies and percentages and were compared with the χ2 test or 
Fisher exact test. The normality of distributions was assessed with 
the Shapiro-Wilk test; comparison of continuous variables was 
done by using the Student t test or Wilcoxon rank-sum test when 
appropriate. A stepwise logistic regression analysis including all 
variables from Tables 1 and 2 exhibiting P<0.10 in the univariable 
analysis was used to determine the predictive factors of AKI and 
30-day mortality. Two interaction terms were tested to evaluate 
synergistic effects of (1) baseline anemia and Hb drop ≤24 hours 
and (2) baseline CKD and contrast load.10 A stepwise Cox regression 
analysis including all variables from Tables 1 and 2 exhibiting 
P<0.10 in the Cox univariable analysis was used to determine the 
predictive factors of long-term mortality in patients who survived the 
first 30 days after TAVI (landmark analysis). For the purpose of this 
Table 1. Baseline Characteristics of Patients With and Without AKI After TAVI
Entire Cohort
(n=995)
No AKI
(n=789)
AKI
(n=206) P  Value
Age, y, median (IQR) 82 (77–86) 82 (78–86) 82 (77–86) 0.42
Male sex, no (%) 497 (50) 393 (50) 104 (50) 0.86
 Height, cm, mean±SD 164±10 164±10 165±10 0.31
 Weight, kg, mean±SD 72±15 71±15 73±16 0.092
 Body mass index, mean±SD 26.4±5.0 26.3±4.8 26.9±5.5 0.14
 Body surface area, mean±SD 1.79±0.21 1.79±0.21 1.82±0.22 0.097
New York Heart Association class ≥III, no (%) 806 (81) 631 (80) 175 (85) 0.11
 Previous cerebrovascular event, no (%) 198 (20) 155 (20) 43 (21) 0.71
 Previous myocardial infarction, no (%) 262 (26) 201 (26) 61 (30) 0.23
 Previous coronary artery bypass graft surgery, no (%) 267 (27) 214 (27) 53 (26) 0.68
 Previous percutaneous coronary intervention, no (%) 303 (31) 239 (30) 64 (31) 0.83
Congestive heart failure, no (%) 577 (58) 442 (56) 135 (66) 0.010
Diabetes mellitus, no (%) 274 (28) 218 (28) 56 (27) 0.90
Hypertension, no (%) 772 (78) 603 (76) 169 (82) 0.085
Peripheral vascular disease, no (%) 301 (30) 222 (28) 79 (39) 0.004
Chronic obstructive pulmonary disease, no (%) 281 (28) 217 (28) 64 (31) 0.31
 Creatinine, median (IQR) 100 (81–129) 99 (81–126) 106 (80–139) 0.12
Chronic kidney disease, no (%)*
 Mild* 243 (24) 198 (25) 45 (22) 0.40
 Moderate* 250 (25) 203 (26) 47 (23)
 Severe* 242 (24) 184 (23) 58 (28)
Hemoglobin, mean±SD 12.2±3.8 12.2±4.2 12.0±1.7 0.42
Anemia, no (%)†
 Mild† 200 (20) 157 (20) 43 (21) 0.82
 Moderate† 192 (19) 150 (19) 42 (20)
 Severe† 175 (18) 136 (17) 39 (19)
Leucocyte count (×109 cells/L), mean±SD 7.3±2.0 7.3±2.2 7.2±2.1 0.55
Atrial fibrillation, no (%) 265 (27) 209 (27) 56 (27) 0.82
Permanent pacemaker, no (%) 133 (13) 100 (13) 33 (16) 0.21
 Left ventricular ejection fraction ≤35%, no (%) 157 (16) 116 (15) 41 (20) 0.068
 Aortic valve area, cm2, mean±SD 0.66±0.19 0.66±0.20 0.66±0.17 0.89
 Peak gradient, mean±SD 71±25 71±25 71±26 0.93
 Mitral regurgitation grade ≥III, no (%) 118 (12) 102 (13) 16 (8) 0.041
 Aortic regurgitation grade ≥III, no (%) 86 (9) 71 (9) 15 (7) 0.44
Logistic Euroscore, median (IQR) 17 (11–30) 15 (10–28) 22 (12–35) <0.001
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; and IQR, interquartile range.
*Chronic kidney disease was defined as a calculated creatinine clearance <60 mL/min; mild 45.0 to 60.0 mL/min, moderate 35.0 to 44.9 mL/min and 
severe <35 mL/min.
†Anemia was defined as Hb <13 g/dL in men and <12 g/dL in women,23 mild anemia 12.0 to 12.99 g/dL in men and 11.30 to 11.99 g/dL in women, moderate anemia 
10.80 to 11.99 g/dL in men and 10.23 to 11.29 g/dL in women, and severe anemia <10.80 g/dL in men and <10.23 g/dL in women.
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study, RBC transfusion was forced into the multivariable analyses 
for predictors of AKI, whereas both RBC transfusion and AKI were 
forced into the multivariable analyses of 30-day and late mortality, 
irrespective of the P value obtained from the univariable analyses. 
Variables included in the multivariable model for the prediction of 
AKI, 30-day mortality, and long-term mortality are listed in online-
only Data Supplement. Results are reported as adjusted OR or 
hazard ratio (HR) with a 95% CI. Survival curves for time-to-event 
variables were constructed on the basis of all available follow-up 
data in patients who survived the first 30 days after TAVI (landmark 
analysis) with the use of Kaplan–Meier estimates and were 
compared with the log-rank test. Patients lost to follow-up (1.6%) 
were considered at risk until the date of last contact, at which point 
they were censored. A 2-sided P<0.05 was considered to indicate 
significance. All statistical analyses were performed with SPSS 
software (version 17).
Results
The baseline patient characteristics and perioperative details 
of the total population and of the patients with and without 
AKI are summarized in Tables 1 and 2, respectively. AKI 
occurred in 20.7% (n=206) of the patients of whom 3.1% 
(n=31) received renal replacement therapy. Details of AKI 
(stages I–III) and other changes in renal function are depicted 
in Figure 1. Patients with AKI had a significantly higher mor-
tality at 30 days and during follow-up (Table 2).
Predictors of AKI
By univariable analysis, patients with AKI had a higher preva-
lence of congestive heart failure (66 versus 56%, P=0.010) 
and peripheral vascular disease (39 versus 28%, P=0.004) 
explaining a higher operative risk (Logistic EuroSCORE 22 
Table 2. Perioperative Results for Patients With and Without 
AKI After TAVI
No AKI
(n=789)
AKI
(n=206) P  Value
Intraoperative or ≤24 h
 Access strategy, no (%)
  Transfemoral 561 (71) 130 (63) 0.002
  Transapical 210 (27) 67 (33)
  Transsubclavian 18 (2) 6 (3)
  Transaortic 0 3 (2)
 Circulatory support, no (%) 20 (3) 9 (4) 0.16
 Prosthesis size, mm, no (%)*
  20, 23, 26 517 (66) 146 (71) 0.12
  29, 31 272 (34) 59 (29) 0.12
  Any complication leading to severe 
sustained hypotension, no (%)
24 (3) 8 (4) 0.54
  Life-threatening arrhythmia, no (%) 29 (4) 10 (5) 0.44
  Postimplantation balloon dilation, 
no (%)
130 (16) 39 (19) 0.41
 Contrast volume, mL, mean±SD 142±97 158±96 0.052
  Duration of procedure, min, 
mean±SD
99 (70–156) 105 (70–173) 0.32
  Major vascular complication, 
no (%)
55 (7) 26 (13) 0.008
 Bleeding complication, no (%)
  Life threatening or major,  
  no (%)
104 (13) 37 (18) 0.080
  Life threatening 39 (5) 15 (7) 0.19
 RBC transfusion, no (%)
  None 632 (80) 133 (64) <0.001
  1–2 units 137 (17) 54 (26)
  3–4 units 14 (2) 11 (5)
  ≥5 units 6 (1) 8 (4)
  Hemoglobin drop—uncorrected 
for RBC TF, g/dL, mean±SD
2.3±4.1 2.3±1.7 0.94
  Hemoglobin drop—corrected for 
RBC TF, g/dL, mean±SD
2.7±4.3 3.2±2.7 0.12
Postoperative ≤72 h
  Serum creatinine (μmol/L),  median (IQR)
  Preprocedural 99 (81–126) 106 (80–139) 0.12
  Postprocedural 83 (67–106) 172 (122–229) <0.001
  Creatinine clearance (mL/min), mean±SD
  Preprocedural 48±20 50±27 0.49
  Postprocedural 63±37 33±29 <0.001
  Leucocyte count (×109 cells/L), mean±SD
  Preprocedural 7.3±2.2 7.2±2.1 0.55
  Postprocedural 11.7±4.8 13.0±4.9 0.001
 Hemoglobin (g/dL), mean±SD
  Preprocedural 12.2±4.2 12.0±1.7 0.42
  Postprocedural 9.4±1.5 9.1±1.5 0.011
 RBC transfusion, no (%)
  None 515 (65) 98 (48) <0.001
  1–2 units 209 (27) 63 (31)
(Continued)
Table 2. (Continued).
No AKI
(n=789)
AKI
(n=206) P  Value
  3–4 units 49 (6) 28 (14)
  ≥5 units 16 (2) 17 (8)
In-hospital
 Echocardiography
  Peak gradient, mean±SD 19±11 19±12 0.99
   Mitral regurgitation grade  
≥III, no (%)
62 (9) 10 (6) 0.21
   Aortic regurgitation grade  
≥III, no (%)
40 (6) 10 (5) 0.96
Length of stay (days), median (IQR) 10 (6–14) 13 (8–22) <0.001
Mortality
 ≤30 days 28 (4) 30 (15) <0.001
 ≤30 days cardiac 14 (2) 17 (8) <0.001
 >30 days† 140 (18) 59 (34) <0.001
 >30 days cardiac†‡ 61 (8) 26 (15) <0.001
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; 
RBC, red blood cell; TF transfusion.
*One patient did not receive a valve due to aborted TAVI after failed 
introduction of 18F sheath.
†N=937 patients survived >30 days after TAVI of which 199 patients died at 
a median of 12 (IQR: 4–23) months after TAVI.
‡The cause of death was missing or unknown in 27 of the 199 deaths 
(14%; n=8 in AKI group, n=19 in no AKI group).
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versus 15%, P<0.001, Table 1). They also more often under-
went transapical TAVI (33 versus 27%, P=0.002) and suffered 
more major vascular complications (13 versus 7%, P=0.008, 
Table 2). Despite the latter, there was no difference in periop-
erative blood loss (corrected Hb drop) between patients with 
and without AKI, yet patients with AKI received significantly 
more blood transfusions within 24 and 72 hours after TAVI. 
Because baseline anemia might affect the decision to adminis-
ter blood transfusion, the mean Hb drop and number of blood 
transfusions for patients with no and with various degrees of 
baseline anemia was analyzed (Figure 2A–2B); patients with 
severe baseline anemia had 2.4 times less blood loss but on 
average received 2.3-fold more units of blood transfusions 
in comparison with patients without anemia before TAVI 
(P<0.001). Neither contrast use (P=0.052) nor any of the 
interaction terms (baseline anemia and Hb drop ≤24 hours, 
P=0.31; baseline CKD and contrast load, P=0.10) were sig-
nificantly associated with AKI.
Figure 1. Changes in creatinine 
≤72 hours after transcatheter 
aortic valve implantation.
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Figure 2. Mean percent Hb drop and mean 
number of blood transfusions ≤24 and  
≤72 hours after transcatheter aortic valve 
implantation (TAVI) grouped according to 
various degrees of baseline anemia. Baseline 
anemia was defined as Hb <13 g/dL in men 
and <12 g/dL in women23; mild anemia 12.0 
to 12.99 g/dL in men and 11.30 to 11.99 g/
dL in women, moderate anemia 10.80 to 
11.99 g/dL in men and 10.23 to 11.29 g/dL 
in women, and severe anemia <10.80 g/dL in 
men and <10.23 g/dL in women. Hb indicates 
hemoglobin. A, Mean percent Hb drop ≤24 
and ≤72 hours after TAVI. Percent Hb drop 
≤24 h=(baseline Hb−nadir Hb ≤24 h)/(base-
line Hb); Percent Hb drop ≤72 h=(baseline 
Hb−nadir Hb ≤72 hours)/(baseline Hb). B, 
Mean number of blood transfusions ≤24 and 
≤72 hours after TAVI. AKI indicates acute 
kidney injury.
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In a descending order of the magnitude of the OR, we 
found by multivariable analysis that the number of units of 
blood transfusion ≤24 hours was the strongest predictor of 
AKI (≥5 units, OR, 4.81 [1.45–15.95]; 3–4 units, OR, 3.05 
[1.24–7.53]; 1–2 units, OR, 1.47 [0.98–2.22]), followed by 
peripheral vascular disease (OR, 1.48 [1.05–2.10]), conges-
tive heart failure (OR, 1.43 [1.01–2.03]), leucocyte count 
≤72 hours after TAVI (OR, 1.05 [1.02–1.09]), and Logistic 
EuroSCORE (OR, 1.02 [1.00–1.03]). Potential triggers of 
blood transfusion such as baseline anemia, bleeding-vascu-
lar complications, and perioperative blood loss (corrected 
Hb drop) were not identified as independent predictors of 
AKI (Table 3).
Prognostic Implications
Independent predictors of 30-day mortality consisted of peri-
operative life-threatening bleeding (OR, 6.65 [2.28–19.44]), 
aortic regurgitation post-TAVI (OR, 4.80 [1.78–12.96]), AKI 
(OR, 3.15 [1.56–6.38]), leucocyte count ≤72 hours (OR, 1.13 
[1.06–1.20]), and Logistic EuroSCORE (OR, 1.04 [1.02–1.06], 
Table 4). Mortality during follow-up in patients who survived 
the first 30 days was determined by a mix of patient-related 
variables and by the administration of blood transfusion for 
≤72 hours (≥5 units, HR, 2.54 [1.34–4.81], 3–4 units, HR, 2.03 
[1.26–3.24], 1–2 units, HR, 1.32 [0.94–1.86]) in addition to 
AKI (HR, 1.57 [1.13–2.17], Table 5). Kaplan–Meier survival 
estimates for increasing severity of AKI, baseline anemia, and 
number of transfusions are shown in Figure 3.
Discussion
In this multicenter study including 995 patients who under-
went TAVI we found that AKI occurred in 21% of the patients 
and that the number of perioperative blood transfusions was 
the strongest predictor of AKI but not the clinical indications 
of transfusion (ie, baseline anemia, perioperative vascular-
bleeding complications, or blood loss). AKI was a predictor 
of both short- and long-term mortality, whereas blood transfu-
sion predicted long-term mortality.
The frequency of AKI after TAVI has been reported to 
vary between 12% and 57% in previous but smaller series 
of patients using various definitions of AKI.2–10 The herein 
reported point estimate of 21% most likely reflects the inci-
dence of AKI encountered in clinical practice, given the sam-
ple size and the multicenter nature of this study. Irrespective 
of the true value, AKI poses a clinical problem as it is associ-
ated with an increased mortality at 30 days and beyond. This 
has also been shown by others and suggests that the outcome 
of TAVI may be improved by—among others—implementing 
all measures to prevent AKI.5–10
For that purpose it is essential to understand the pathophysi-
ologic mechanism(s) of AKI after TAVI. Unfortunately, a clin-
ical study such as this one cannot do so, yet the analysis of the 
association between AKI and patient- and procedure-related 
variables that are readily available (eg, patient demographics) 
or subject to change or improvement (eg, execution of proce-
dure) may be helpful.
With respect to execution of the procedure, the findings 
of this study indicate that AKI and, therefore, outcome may 
be improved by a more careful use of blood transfusions. 
As mentioned, the number of blood transfusions was found 
Table 4. Independent Predictors of Mortality ≤30 Days After 
Transcatheter Aortic Valve Implantation
Variable OR (95% CI) P  Value
Life-threatening bleeding 6.65 (2.28–19.44) 0.001
Post operative aortic regurgitation 
grade ≥III
4.80 (1.78–12.96) 0.002
Acute kidney injury 3.15 (1.56–6.38) 0.001
Maximum leucocyte count ≤72 h  
(per 109 cells/L increase)
1.13 (1.06–1.20) <0.001
Logistic EuroSCORE (per % increase) 1.04 (1.02–1.06) <0.001
RBC transfusion ≤24 h
 None Reference 0.72
 1–2 units 0.76 (0.33–1.75) 0.51
 3–4 units 0.31 (0.03–3.06) 0.31
 ≥5 units 1.01 (0.15–6.73) 0.99
Table 5. Independent Predictors of Mortality >30 Days After 
Transcatheter Aortic Valve Implantation
Variable HR (95% CI) P  Value
RBC transfusion ≤72 h
 None Reference 0.004
 1–2 units 1.32 (0.94–1.86) 0.11
 3–4 units 2.03 (1.26–3.24) 0.003
 ≥5 units 2.54 (1.34–4.81) 0.004
Baseline anemia
 None Reference 0.005
 Mild 0.85 (0.54–1.34) 0.48
 Moderate 1.49 (1.01–2.20) 0.043
 Severe 1.75 (1.18–2.60) 0.005
Acute kidney injury 1.57 (1.13–2.17) 0.007
Peripheral vascular disease 1.69 (1.25–2.30) 0.001
Congestive heart failure 1.62 (1.16–2.26) 0.004
Male sex 1.53 (1.14–2.06) 0.005
Atrial fibrillation 1.46 (1.06–1.99) 0.019
RBC denotes red blood cell.
Table 3. Independent Predictors of AKI After TAVI
Variable OR (95% CI) P  Value
RBC transfusion ≤24 h
 None Reference 0.003
 1–2 units 1.47 (0.98–2.22) 0.064
 3–4 units 3.05 (1.24–7.53) 0.015
 ≥5 units 4.81 (1.45–15.95) 0.010
Peripheral vascular disease 1.48 (1.05–2.10) 0.026
Congestive heart failure 1.43 (1.01–2.03) 0.042
Maximum leucocyte count ≤72 h  
(per 109 cells/L increase)
1.05 (1.02–1.09) 0.001
Logistic EuroSCORE (per % increase) 1.02 (1.00–1.03) 0.006
AKI indicates acute kidney injury; TAVI, transcatheter aortic valve implantation; 
RBC, red blood cell.
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to be the strongest predictor of AKI with a distinct gradient 
of risk. The relation between AKI and transfusion is consis-
tent with other reports that studied patients who underwent 
TAVI or cardiac surgery,5,6,10,26,27 yet, such a strong relation-
ship between AKI and the number of transfusions has not 
been reported. Noteworthy, we also found that the clinical 
triggers upon which one may decide to administer blood 
during TAVI were not associated with AKI. If true, this sug-
gests that one should be more restrictive in the use of blood 
transfusions during TAVI and that the need of unequivocal 
criteria for the decision of blood transfusion is advocated. 
This is illustrated by the findings that patients without ane-
mia had a 2.4 times greater Hb drop in comparison with 
patients with severe baseline anemia. This may be explained 
by a different patient and procedure planning in addition to 
differences in the execution of TAVI (ie, control of hemo-
stasis) in patients with different baseline risks. Interventions 
that reduce perioperative transfusions may protect against 
AKI, especially in anemic patients.27
The absence of a relationship between AKI and the indications 
for transfusion in addition to the fact that we did not find a rela-
tionship between AKI and periprocedural complications leading 
to hypotension supports a direct harmful effect of transfusion on 
the kidneys. It is known that preserved RBCs suffer structural or 
functional changes including reduced deformability and increased 
aggregability, all of which—particularly in older patients with 
impaired renal function—might induce (further) renal dysfunc-
tion.28 Also the coadministration of proinflammatory molecules 
may play a role either directly or indirectly by inducing inflam-
mation.29 This may explain the relation found in this and other 
studies between postoperative leucocyte count and AKI.4,6,10,30
At variance with percutaneous coronary intervention (PCI),31 
we found a borderline association between contrast load and 
AKI in the univariable analysis, yet contrast load was not found 
to be an independent predictor. The absence of an association 
cannot be explained by a restrictive use of contrast in the pres-
ent population considering the mean values and standard devia-
tions (142±97 and 158±96 mL) although this may be an issue 
of sample size as a result of which a significant statistical differ-
ence was not detected. The current findings suggest that unlike 
PCI, contrast has only a minor effect on the development of 
AKI in patients who undergo TAVI.
With respect to the patient-related variables and, thus, 
patient selection, it is unlikely that we will exclude patients 
with peripheral vascular disease because TAVI was specifi-
cally developed for patients who are too high a risk for aortic 
Figure 3. Time-to-event curves for selected risk factors in patients who survived the first 30 days after transcatheter aortic valve 
 implantation (TAVI) (landmark analysis). Event rates were calculated with the use of Kaplan–Meier methods and compared with the use of 
the log-rank test. A, Time-to-event curves for patients without acute kidney injury (AKI), AKI-stage I and with AKI-stage II or III after TAVI. 
B, Time-to-event curves for patients without transfusions, 1–2 transfusions and with >2 transfusions ≤72 h after TAVI. C, Time-to-event 
curves for patients with no and various degrees of baseline anemia. Baseline anemia was defined as Hb <13 g/dL in men and <12 g/dL 
in women23; mild anemia 12.0 to 12.99 g/dL in men and 11.30 to 11.99 g/dL in women, moderate anemia 10.80 to 11.99 g/dL in men and 
10.23 to 11.29 g/dL in women, and severe anemia <10.80 g/dL in men and <10.23 g/dL in women. Hb indicates hemoglobin.
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the kidneys. It is known that preserved RBCs suffer structural or 
functional changes including reduced deformability and increased 
aggregability, all of which—particularly in older patients with 
impaired renal function—might induce (further) renal dysfunc-
tion.28 Also the coadministration of proinflammatory molecules 
may play a role either directly or indirectly by inducing inflam-
mation.29 This may explain the relation found in this and other 
studies between postoperative leucocyte count and AKI.4,6,10,30
At variance with percutaneous coronary intervention (PCI),31 
we found a borderline association between contrast load and 
AKI in the univariable analysis, yet contrast load was not found 
to be an independent predictor. The absence of an association 
cannot be explained by a restrictive use of contrast in the pres-
ent population considering the mean values and standard devia-
tions (142±97 and 158±96 mL) although this may be an issue 
of sample size as a result of which a significant statistical differ-
ence was not detected. The current findings suggest that unlike 
PCI, contrast has only a minor effect on the development of 
AKI in patients who undergo TAVI.
With respect to the patient-related variables and, thus, 
patient selection, it is unlikely that we will exclude patients 
with peripheral vascular disease because TAVI was specifi-
cally developed for patients who are too high a risk for aortic 
valve replacement. These patients often have widespread ath-
erosclerosis including the peripheral circulation. It remains to 
be seen how additional pre- and postoperative care may avoid 
AKI such as optimal perioperative hydration.
Apart from perioperative blood transfusion and AKI, we 
found a number of other predictors of early and late mortality 
after TAVI. In accordance with previous series, we found severe 
bleeding and postoperative aortic regurgitation to be associated 
with a 5-fold increased risk of early death,32 whereas severe 
baseline anemia, peripheral vascular disease, heart failure, 
male sex, and atrial fibrillation were independent predictors 
of late death.12,33,34 These findings confirm the importance of 
appropriate patient selection to improve outcome after TAVI.
Limitations
This multicenter observational assessment in a large series 
of patients may estimate the frequency of AKI and its pre-
dictors but it cannot elucidate the precise pathophysiologic 
mechanism(s). This is needed to propose in greater detail 
improvements in patient and procedure planning and execu-
tion in addition to eventual changes in postoperative care. We 
also acknowledge the formulation of the research question 
during and after the data collection and the absence of a pre-
specified case report form. As a result, despite a high degree 
of completeness (online-only Data Supplement), the timing of 
the collection of the individual variables may not be consis-
tent, which may affect the precision of the current findings. In 
addition, there was no uniform protocol of blood transfusion, 
as a result of which we were are not able to unravel the true 
triggers of transfusion, thereby precluding specific proposi-
tions of improvement.
Conclusions
AKI occurred in 21% of the patients after TAVI. The num-
ber of blood transfusions, but not the indication of transfu-
sion, predicted AKI. AKI was a predictor of both short- and 
long-term mortality, whereas blood transfusion predicted 
long-term mortality. These findings indicate that the outcome 
of TAVI may be improved by a more restrictive use of blood 
transfusions.
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